Table 2.
Immunophenotypic and genetic features of other B-cell lymphomas that may be confused with CLL
| Neoplasm | SIg | cIg | CD5 | CD10 | CD23 | CD43 | Cyclin D1 | Bcl-6 protein* | Genetic abnormality (%) | IgVH genes |
|---|---|---|---|---|---|---|---|---|---|---|
| CLL | + | −/+ | + | − | + | + | − | − | del13q (50); del 11q (20); trisomy 12 (20); del 17p (10) | 50% unmutated |
| LPL | + | + | − | − | − | −/+ | − | − | t(9;14)-PAX5R | Mutated |
| MCL | + | − | + | − | − | + | + | − | t(11;14)-BCL1R | Unmutated (rarely mutated) |
| FL | + | − | − | + | −/+ | − | − | + | t(14;18)-BCL2R | Mutated, ongoing |
| Extranodal and nodal MZL | + | −/+ | − | − | −/+ | −/+ | − | − | trisomy 3; t(11;18)-API2/MLT; t(1;14)-BCL10R | Mutated, ongoing |
| Splenic MZL | + | −/+ | − | − | − | − | − | − | del 7q21-32 (40) | 50% mutated |
LPL indicates lymphoplasmacytic lymphoma; MCL, mantle cell lymphoma; FL, follicle center lymphoma; MZL, marginal zone lymphoma; +, more than 90% positive; −/+, less than 50% positive; and −, less than 10% positive.
*
Residual GC may be + in MZL, MCL.